Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood

[1]  S. Franco,et al.  Clinical Experience with Trastuzumab (Herceptin) , 2003, The breast journal.

[2]  A. Forero,et al.  History of antibody therapy for non-Hodgkin's lymphoma. , 2003, Seminars in oncology.

[3]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[4]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[5]  S. Ménard,et al.  Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 , 2004, Clinical Cancer Research.

[6]  J. Baselga,et al.  Mechanism of action of anti-HER2 monoclonal antibodies. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Shigeru Iida,et al.  Establishment of FUT8 knockout Chinese hamster ovary cells: An ideal host cell line for producing completely defucosylated antibodies with enhanced antibody‐dependent cellular cytotoxicity , 2004, Biotechnology and bioengineering.

[8]  M. Goldenberg.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. , 1999, Clinical therapeutics.

[9]  J. Belaiche,et al.  Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease , 2004, Alimentary pharmacology & therapeutics.

[10]  J. Ledbetter,et al.  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells , 2000, Cancer Immunology, Immunotherapy.

[11]  S. Iida,et al.  Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies , 2006, Expert opinion on biological therapy.

[12]  P. Colombat,et al.  Rituximab-Dependent Cytotoxicity by Natural Killer Cells , 2004, Cancer Research.

[13]  A. Wolf,et al.  High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. , 2006, Molecular immunology.

[14]  Uwe Schauer,et al.  IgG subclass concentrations in certified reference material 470 and reference values for children and adults determined with the binding site reagents. , 2003, Clinical chemistry.

[15]  I. Sanz,et al.  The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus , 2003 .

[16]  S. Iida,et al.  Enhanced binding affinity for FcgammaRIIIa of fucose-negative antibody is sufficient to induce maximal antibody-dependent cellular cytotoxicity. , 2007, Molecular immunology.

[17]  T. Hayakawa,et al.  Profiling analysis of oligosaccharides in antibody pharmaceuticals by capillary electrophoresis. , 2004, Journal of chromatography. A.

[18]  E. Kimby,et al.  Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  S. Iida,et al.  Nonfucosylated Therapeutic IgG1 Antibody Can Evade the Inhibitory Effect of Serum Immunoglobulin G on Antibody-Dependent Cellular Cytotoxicity through its High Binding to FcγRIIIa , 2006, Clinical Cancer Research.

[20]  Akira Okazaki,et al.  Comparison of biological activity among nonfucosylated therapeutic IgG1 antibodies with three different N-linked Fc oligosaccharides: the high-mannose, hybrid, and complex types. , 2007, Glycobiology.

[21]  M. Kiso,et al.  Analysis of oligosaccharides of human IgG from serum of leukemia patients. , 1994, Biochemistry and molecular biology international.

[22]  G. A. Lazar,et al.  Engineered antibody Fc variants with enhanced effector function. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  E. Rowinsky,et al.  The ErbB receptor family: a therapeutic target for cancer. , 2002, Trends in molecular medicine.

[24]  M. Schenerman,et al.  Comparability testing of a humanized monoclonal antibody (Synagis) to support cell line stability, process validation, and scale-up for manufacturing. , 1999, Biologicals : journal of the International Association of Biological Standardization.

[25]  T. Illidge,et al.  A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells. , 2004, Blood.

[26]  A. Shimizu,et al.  Structural and numerical variations of the carbohydrate moiety of immunoglobulin G. , 1982, Journal of immunology.

[27]  T. Bentley,et al.  Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS/WHO collaborative study. , 1992, Immunology letters.

[28]  P. Carter,et al.  Improving the efficacy of antibody-based cancer therapies , 2001, Nature Reviews Cancer.

[29]  A. Grillo‐López.  Rituximab (Rituxan®/MabThera®): the first decade (1993–2003) , 2003, Expert review of anticancer therapy.

[30]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  A. Makino,et al.  Structural studies on IgG oligosaccharides of patients with primary Sjögren's syndrome , 2004, Glycoconjugate Journal.

[32]  M. Glennie,et al.  Renaissance of cancer therapeutic antibodies. , 2003, Drug discovery today.

[33]  T. Bentley,et al.  Evaluation of monoclonal antibodies having specificity for human IgG subclasses: results of the 2nd IUIS/WHO collaborative study. , 1992, Immunology letters.

[34]  Mitchell R. Smith.  Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance , 2003, Oncogene.

[35]  S. Miescher,et al.  A single recombinant anti-RhD IgG prevents RhD immunization: association of RhD-positive red blood cell clearance rate with polymorphisms in the FcgammaRIIA and FcgammaIIIA genes. , 2004, Blood.

[36]  Y. Vugmeyster,et al.  Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. , 2004, International immunopharmacology.

[37]  N. Kochibe,et al.  Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns. , 1987, Analytical biochemistry.

[38]  R. Kircheis,et al.  Compensation of endogenous IgG mediated inhibition of antibody-dependent cellular cytotoxicity by glyco-engineering of therapeutic antibodies. , 2007, Molecular immunology.

[39]  Y. Vugmeyster,et al.  Effect of anti‐CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[40]  Janice M Reichert,et al.  Monoclonal antibody successes in the clinic , 2005, Nature Biotechnology.

[41]  M. Czuczman,et al.  Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.